GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » Gross Profit

Phathom Pharmaceuticals (Phathom Pharmaceuticals) Gross Profit : $0.68 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Phathom Pharmaceuticals Gross Profit?

Phathom Pharmaceuticals's gross profit for the three months ended in Dec. 2023 was $0.68 Mil. Phathom Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.68 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Phathom Pharmaceuticals's gross profit for the three months ended in Dec. 2023 was $0.68 Mil. Phathom Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.68 Mil. Therefore, Phathom Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Phathom Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 6 years, the highest Gross Margin % of Phathom Pharmaceuticals was 75.51%. The lowest was 75.51%. And the median was 75.51%.


Phathom Pharmaceuticals Gross Profit Historical Data

The historical data trend for Phathom Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phathom Pharmaceuticals Gross Profit Chart

Phathom Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial - - - - 0.52

Phathom Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.68

Competitive Comparison of Phathom Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Phathom Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phathom Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's Gross Profit falls into.



Phathom Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Phathom Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.682 - 0.167
=0.52

Phathom Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.682 - 0
=0.68

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.68 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Phathom Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.68 / 0.682
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Phathom Pharmaceuticals  (NAS:PHAT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Phathom Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Phathom Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Phathom Pharmaceuticals (Phathom Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Executives
Molly Henderson officer: CFO and CBO 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Asit Parikh director C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Azmi Nabulsi officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Terrie Curran director C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
David A Socks director, officer: President, CEO, Treas. & Sec. C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Anthony J. Guzzo officer: VP, Chief Accounting Officer C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse director 5505 ENDEAVOR LANE, MADISON WI 53719
Michael F Cola director 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Frazier Life Sciences Ix, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Jonathan S. Edwards director C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Phathom Pharmaceuticals (Phathom Pharmaceuticals) Headlines

From GuruFocus